The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP CRN Competitive Renewal Opportunity, 2024Investigating How Alpha-synuclein-rich Neurons in Olfactory Circuits Respond to Environmental Triggers at the Initiation of Parkinson Disease
Study Rationale: To slow the progression of Parkinson disease (PD), we need to understand how, where and why the illness starts. It is estimated that most individuals with PD experience a significant...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Translational Investigation of Drugs that Modulate Circadian Rhythm in Models of Parkinson’s Disease
Study Rationale: Recent studies suggest that sleep problems can worsen Parkinson’s disease (PD) by affecting chemicals in the brain and causing inflammation. It's also possible that sleep problems...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Brain-specific LRRK Inhibitors for Parkinson’s Disease
Study Rationale: Mutations in LRRK2 are thought to be causative for Parkinson’s disease (PD), but increases in LRRK2 activity have also been observed in non-familial cases of PD. As a result, LRRK2...
-
Freezing of Gait Program, 2024Use of Neuromodulation to Relieve Gait Freezing in Parkinson’s Disease
Study Rationale: Almost all individuals with Parkinson’s disease (PD) develop episodes of freezing of gait, which is a sudden inability to take a step while walking. Gait freezing can cause falls that...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Study of Multiple Air Pollutants in Parkinson’s Disease (MAP-PD)
Study Rationale: Chemicals in our environment, including some air pollutants, likely contribute to the development of Parkinson’s disease (PD). However, relatively few chemicals have been identified...
-
Accelerating Biological Understanding and Therapeutic Translation For Parkinson’s Disease- Biology, 2024Establishing a Cohort of Carriers with ATP13A2 Mutations for Clinical and Biomarker Analysis
Study Rationale: Polyamines are molecules that show neuroprotective effects, and one of the genes that is mutated in Parkinson’s disease (PD), ATP13A2, regulates cellular polyamine levels. Unpublished...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.